HIF-1 as a target for drug development
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, growing evidence showed that the strong cell–cell contacts of tumor spheroids in combination with dense ECM deposition is responsible for chemoresistance by posing a physical barrier to the penetration of chemotherapeutics and immune cells similar to in vivo.[ 48 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [48]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Most importantly, overexpression of HIF-1α or HIF-2α have been implicated as poor prognostic indicators for a variety of tumour”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Research works printed but not linked: 1
- Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206–210 (1997). · DOI · Paper page
Cited by
Items 401–500 of 671
Zhou, X., Chen, M., Zheng, Z., Zhu, G., Jiang, Z., & Bai, L. (2017) · RSC Advances · doi:10.1039/c7ra02238g · Cited by 18
Wang, L., Ji, S., Liu, Z., & Zhao, J. (2022) · Chemotherapy · doi:10.1159/000523905 · Cited by 18
2 ME 2 increase radiation‐induced apoptosis of keloid fibroblasts by targeting HIF ‐1α in vitro
Long, F., Si, L., Long, X., Yang, B., Wang, X., & Zhang, F. (2015) · Australasian Journal of Dermatology · doi:10.1111/ajd.12340 · Cited by 19
Ao, J.-E., Kuang, L., Zhou, Y., Zhao, R., & Yang, C. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.03.101 · Cited by 18
Palayoor, S. T., Burgos, M. A., Shoaibi, A., Tofilon, P. J., & Coleman, C. N. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0005 · Cited by 18
Development of novel inhibitors targeting HIF-1α towards anticancer drug discovery
Yewalkar, N., Deore, V., Padgaonkar, A., Manohar, S. M., Sahu, B., Kumar, P., Jalota‐Badhwar, A., Joshi, K. S., Sharma, S., & Kumar, S. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.09.083 · Cited by 20
Thymosin β4 promotes autophagy and repair via HIF-1α stabilization in chronic granulomatous disease
Renga, G., Oikonomou, V., Moretti, S., Stincardini, C., Bellet, M. M., Pariano, M., Bartoli, A., Brancorsini, S., Mosci, P., Finocchi, A., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900432 · Cited by 18
“…as an antitumor Tβ4 stabilizes HIF-1a in chronic granulomatous disease Renga et al. https://doi.org/10.26508/lsa.201900432 vol 2 | no 6 | e201900432 5 of 12 therapeutic strategy, up-regulation of HIF-1α is critical in the treatment of ischemic states (Giaccia et al, 2003; Yee Koh et al, 2008).”
BackgroundInfluentialEffective delivery of mycophenolic acid by oxygen nanobubbles for modulating immunosuppression
Khan, M. S., Js, K., Hwang, J., Choi, Y., Lee, K., Kwon, Y., Jang, J., Yoon, S., Yang, C., & Choi, J. H. (2020) · Theranostics · doi:10.7150/thno.41850 · Cited by 17
“In this study, we aimed to downregulate HIF-1α, which might prove to be beneficial for suppressing the immune response [42,50].”
BackgroundLiu, C., Liu, H., Fang, Y., Jiang, S., Zhu, J., & Ding, X. (2014) · Clinical and investigative medicine · doi:10.25011/cim.v37i3.21381 · Cited by 17
“In addition, the PI3K signaling pathway is involved in the HIF-1 signaling pathway, and the downstream e ector of the PI3K is mTOR [9], which can be inhibited by rapamycin. is may be another mechanism by which rapamycin alleviates renal hypoxia.”
BackgroundInfluentialEffect of conjugated linoleic acid on inhibition of prolyl hydroxylase 1 in hearts of mice
Zhang, J., & Li, D. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-22 · Cited by 17
“The availability of less cumbersome non-toxic inhibitors of PHDs has been proved very useful for therapeutic intervention [11-13].”
BackgroundLiu, J., Zhu, Y., Chen, S., Shen, B., Yu, F., Zhang, Y., & Shen, R. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000491720 · Cited by 17
Oxygen Pathology and Oxygen-Functional Materials for Therapeutics
Huo, M., Wang, L., Chen, Y., & Shi, J. (2020) · Matter · doi:10.1016/j.matt.2020.02.013 · Cited by 18
Convergent total synthesis of the racemic HIF-1 inhibitor laurenditerpenol
Jung, M. E., & Im, G.-Y. J. (2008) · Tetrahedron Letters · doi:10.1016/j.tetlet.2008.05.116 · Cited by 17
Dai, M., Miao, Z., Ren, X., Tong, L., Yang, N., Li, T., Lin, L., Shen, Y., & Ding, J. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00822.x · Cited by 16
“These features make it an attractive target of new cancer therapeutics [1, 2].”
BackgroundLü, Y., Li, X., Lu, H., & Fan, Z. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015823 · Cited by 16
“Alternatively, the HIF-1a protein can be targeted indirectly by regulating its protein synthesis or stability using pharmacologic strategies that can be tested clinically [19].”
BackgroundHong, Y. R., Kim, H. T., Ro, S., Cho, J. M., Lee, S. H., Kim, I. S., & Jung, Y. H. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.05.003 · Cited by 17
Modifying microbially derived short chain fatty acids to promote health
Ornelas, A., Countess, J. A., Kim, J. Y., & Colgan, S. P. (2025) · The Journal of Physiology · doi:10.1113/jp287585 · Cited by 17
“HIF is a master transcriptional regulator of many genes involved in angiogenesis, erythropoiesis, barrier formation, energy metabolism and inflammation (Giaccia et al., 2003).”
Chlorogenic acid modulates hypoxia response of Hep3B cells
Siswanto, F. M., Oguro, A., & Imaoka, S. (2017) · Personalized Medicine Universe · doi:10.1016/j.pmu.2017.03.001 · Cited by 15
CDCA8 promotes bladder cancer survival by stabilizing HIF1α expression under hypoxia
Zhou, Q., Huang, W., Xiong, J., Guo, B., Wang, X., & Guo, J. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-06189-x · Cited by 15
Schipani, E. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.05236.x · Cited by 15
Zhu, Y., Cuevas, I., Gabriel, R. A., Su, H., Nishimura, S. L., Gao, P., Fields, A., Qi, H., Young, W. L., Yang, G., et al. (2009) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181a491ce · Cited by 15
“During hypoxia, the HIF-1> subunit is stabilized, and its normal degradation is inhibited (22, 25).”
BackgroundChoi, H., Gillespie, D. L., Berg, S., Rice, C., Couldwell, S., Gu, J., Colman, H., Jensen, R. L., & Huang, E. L. (2015) · PLoS ONE · doi:10.1371/journal.pone.0125125 · Cited by 15
Stabilization of enzyme-immobilized hydrogels for extended hypoxic cell culture
Hudson, B. N., Dawes, C. S., Liu, H., Dimmitt, N. H., Chen, F., Koenig, H., & Lin, C. (2019) · Emergent Materials · doi:10.1007/s42247-019-00038-4 · Cited by 15
“Higher expression of HIF-1α, the master regulator of cellular adaptive response to hypoxia [35, 36], suggested that the cells still experienced hypoxic condition at day-14.”
BackgroundThe Role of Oxygen Sensors, Hydroxylases, and HIF in Cardiac Function and Disease
Townley-Tilson, W. H. D., Pi, X., & Xie, L. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/676893 · Cited by 17
“), no specific dehydroxylase has been uncovered yet, though speculation of its/their existence has been postulated [113].”
BackgroundErythropoietin Is More than Just a Promoter of Erythropoiesis
Pfeilschifter, J. M., & Huwiler, A. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000136297.12121.96 · Cited by 15
“Moreover, the success story of EPO provides a case in point that targeting the central hypoxia signaling devices, such as HIF-1 may provide an attractive target for future drug development (17).”
BackgroundNatural Product Sources of Drugs: Plants, Microbes, Marine Organisms, and Animals
Cragg, G. M. L., & Newman, D. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00011-0 · Cited by 15
Naik, R., Han, S.-H., & Lee, K. (2015) · Archives of Pharmacal Research · doi:10.1007/s12272-015-0632-5 · Cited by 15
Hong, Y. R., Kim, H. T., Lee, S., Ro, S., Cho, J. M., Kim, I. S., & Jung, Y. H. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.08.067 · Cited by 15
Li, Y., Zhao, X., Tang, H., Zhong, Z., Zhang, L., Xu, R., Li, S., & Wang, Y. (2011) · Urologia Internationalis · doi:10.1159/000331881 · Cited by 16
NSD1 promotes esophageal cancer tumorigenesis via HIF1α signaling
He, F., Xiao, H., Cai, Y., & Zhang, N. (2022) · Cell Biology and Toxicology · doi:10.1007/s10565-022-09786-2 · Cited by 14
“HIF1/VEGFA signaling pathway is crucial in tumor angiogenesis (Giaccia et al. 2003; Sharp and Bernaudin 2004; Eswarappa and Fox 2015).”
BackgroundOxygen dynamics and delivery strategies to enhance beta cell replacement therapy
Shang, K., Suzuki, T., Kato, H., Toyoda, T., Tai, Y., & Komatsu, H. (2025) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00984.2024 · Cited by 16
Wenger, J. B., Santos, N., Liu, Y., Dallas, J., Subbiah, S., Hochwald, S. N., Huang, E. H., Dang, D. T., Allegra, C. J., Luesch, H., et al. (2011) · Oncology Reviews · doi:10.1007/s12156-011-0082-3 · Cited by 14
Gao, Y., Li, C., Wang, H., & Fan, G.-Y. (2015) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-015-0219-3 · Cited by 14
Cao, X., Wu, W., Wang, D. W., Sun, W., & Lai, S. (2022) · Cell Communication and Signaling · doi:10.1186/s12964-022-00825-3 · Cited by 16
“A hallmark of this progression is upregulation of hypoxiainducible factor 1α expression, coupled with abnormal elevation of vessel angiogenesis [15, 16].”
BackgroundGilani, K., & Vafakhah, M. (2010) · Archives of Advances in Biosciences · doi:10.22037/jps.v1i2.1616 · Cited by 33
Truncated forms of BNIP3 act as dominant negatives inhibiting hypoxia-induced cell death
Bristow, N. A., Burton, T. R., Henson, E. S., Ong-Justiniano, C. M. Q., Brown, M., & Gibson, S. B. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.11.013 · Cited by 15
“HIF-1 is central to most hypoxia responses, and as such, inhibition of HIF-1 activity may be important in combinatory cancer therapy [29].”
BackgroundKim, Y. J., Park, S. J., Kim, N. R., & Chin, H. S. (2017) · Korean Journal of Ophthalmology · doi:10.3341/kjo.2017.31.1.80 · Cited by 15
“Therapeutics that target HIF-1α have been studied thoroughly in the field of cancer treatment and many agents that target HIF-1α directly have been developed [18-23].”
BackgroundMolecular Recognition of DNA by Py–Im Polyamides: From Discovery to Oncology
Dervan, P. B., Kurmis, A. A., & Finn, P. B. (2018) · Royal Society of Chemistry eBooks · doi:10.1039/9781788012928-00298 · Cited by 17
Ramamoorthy, P., Xu, G., & Shi, H. (2018) · Neurochemical Research · doi:10.1007/s11064-018-2516-9 · Cited by 14
“In normal physiological condition, HIF-1α is hydroxylated by prolyl-4-hydroxylase domains (PHD), ubiquitinated, and rapidly degraded by the 26S proteosomal degradation pathway [32].”
Synthesis and Evaluation of Bakuchiol Derivatives as Potential Anticancer Agents
Wu, C., Liu, D., Guo, X. H., Dai, Y., Ma, T., Li, H., & Huo, Q. (2018) · Molecules · doi:10.3390/molecules23030515 · Cited by 15
“Therefore, HIF-1α inhibitors are considered potential therapeutic agents for cancer [16,17].”
BackgroundVitamin D and Hypoxia: Points of Interplay in Cancer
Gkotinakou, I., Mylonis, I., & Tsakalof, A. K. (2022) · Cancers · doi:10.3390/cancers14071791 · Cited by 15
Li, T., Liu, X., Yang, B., Wang, Z., Chen, Y., Jin, X., & Shen, C. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.03.004 · Cited by 13
Peptide/protein-based macrocycles: from biological synthesis to biomedical applications
Wu, W., Guo, J., Zhang, L., Zhang, W., & Gao, W. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00246e · Cited by 13
Xu, H., Wang, J., Chen, Y., Du, Y., Chen, L., Wu, C., Wang, L., & Chen, G. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115171 · Cited by 14
A trip through the signaling pathways of melanoma
Fensterle, J. (2006) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/j.1610-0387.2006.05925.x · Cited by 17
Roles of Angiogenesis and Vascular Remodeling in Brain Vascular Malformations
Hashimoto, T., & YOUNG, W. (2004) · Seminars in Cerebrovascular Diseases and Stroke · doi:10.1053/j.scds.2005.01.006 · Cited by 15
Pfander, C., Knauth, K., Dambacher, S., & Buchberger, A. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm932 · Cited by 14
“Further future applications of the system could include screens for therapeutically relevant chemical compounds that specifically alter the interaction between pVHL and HIF1/2a (4,49,50).”
BackgroundHIF-1α inhibition by MO-2097, a novel chiral-free benzofuran targeting hnRNPA2B1
Han, H. J., Sivaraman, A., Kim, M., Min, K. H., Song, M. E., Choi, Y., Choi, W.-J., Han, H., Han, J., Jang, J., et al. (2023) · Journal of Advanced Research · doi:10.1016/j.jare.2023.11.016 · Cited by 12
Gao, T., Wang, R. Y., Zhang, H., & Zhao, F. (2022) · Journal of Chromatography B · doi:10.1016/j.jchromb.2022.123435 · Cited by 12
Tsui, L., Fong, T.-H., & Wang, I. (2012) · PubMed Central · Cited by 13
Lakka, A., Mylonis, I., Bonanou, S., Simos, G., & Tsakalof, A. K. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9440-4 · Cited by 13
“Therefore, HIF-1 inhibition has been suggested as a therapeutic strategy in cancer and HIF-1 has been validated as a drug target [5–7].”
BackgroundLi, C., Liu, D., Zhang, Z., Wang, G., & Xu, N. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9541-8 · Cited by 12
Dihydrotanshinone I inhibits the translational expression of hypoxia-inducible factor-1α
Li, J., Mi, C., Ma, J., Wang, K. S., Lee, J. J., & Jin, X. (2015) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2015.08.006 · Cited by 12
Li, W., Hu, K., Zhang, Q., Wang, D., Ma, Y., Hou, Z., Yin, F., & Li, Z. (2018) · Chemical Communications · doi:10.1039/c7cc09201f · Cited by 12
Discovery of bicyclo[3,3,1]non-2-ene as a novel skeleton for HIF-1 inhibitors
Ueda, H., Yoshimori, A., & Nakamura, H. (2018) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2018.05.002 · Cited by 13
Huang, W., Chen, S.-T., Chang, W., Chang, K., Chang, W., & Chen, B. (2010) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-010-0392-9 · Cited by 14
“genes involved in tumorigenesis [32].”
Hypoxia, Gene Expression, and Metastasis
Razorenova, O. V., & Giaccia, A. J. (2010) · Springer eBooks · doi:10.1007/978-1-4419-6615-5_3 · Cited by 14
Self-citationA closer look at the role of deubiquitinating enzymes in the Hypoxia Inducible Factor pathway
Pauzaite, T., & Nathan, J. A. (2024) · Biochemical Society Transactions · doi:10.1042/bst20230861 · Cited by 11
Anticancer Activity of Natural Flavonoids: Inhibition of HIF-1α Signaling Pathway
Deng, X., Peng, Y., Zhao, J., Lei, X., Zheng, X., Xie, Z., & Tang, G. (2019) · Current Organic Chemistry · doi:10.2174/1385272823666191203122030 · Cited by 13
Inhibitory effect of zinc on hypoxic HIF-1 activation in astrocytes
Kim, I., Kim, C. H., Seo, G. H., Kim, H. S., Lee, J., Kim, D. G., & Ahn, Y. S. (2008) · Neuroreport · doi:10.1097/wnr.0b013e328304d9ac · Cited by 11
Neddylation blockade induces HIF-1α driven cancer cell migration via upregulation of ZEB1
Park, J. B., Seo, J., Park, J., & Chun, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-75286-0 · Cited by 12
Yamada, N., Kato‐Kogoe, N., Yamanegi, K., Nishiura, H., Fujihara, Y., Fukunishi, S., Okamura, H., Terada, N., & Nakasho, K. (2018) · Anticancer Research · doi:10.21873/anticanres.12358 · Cited by 13
Braliou, G. G., Venieris, E., Kalousi, A., & Simos, G. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.06.043 · Cited by 15
Geetha, A. V. S., Harithpriya, K., Ganesan, K., & Ramkumar, K. M. (2025) · Current Oncology · doi:10.3390/curroncol32020106 · Cited by 10
“Ultimately, effective targeting of HIF-1 α , along with other potential biomarkers, may enhance patient outcomes, reduce mortality, and alleviate the socioe-Curr”
Kong, L., Wang, L., Zhang, Z., Ye, L., Chan, D. S., Wong, C.-Y., Wang, J., Leung, C., & Wang, W. (2025) · Redox Biology · doi:10.1016/j.redox.2025.103805 · Cited by 10
“At the same time, excessive ROS could activate hypoxia-inducible factor-1 α (HIF-1 α ) in a hypoxia-independent manner [54], promoting the development of inflammatory diseases [55].”
Keith, B., & Simon, M. C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4066-6.00017-2 · Cited by 11
The effect of surgically induced ischaemia on gene expression in a colorectal cancer xenograft model
Atkin, G. K., Daley, F. M., Bourne, S., Glynne‐Jones, R., Northover, J. M. A., & Wilson, G. D. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602905 · Cited by 10
“Unlike the protein response, hypoxia has been shown to have little effect on HIF-1a transcription in cell culture (Giaccia et al, 2003).”
BackgroundNelson, D. W., Cao, H., Zhu, Y., Sunar‐Reeder, B., Choi, C. Y. H., Faix, J. D., Brown, J. M., Koong, A. C., Giaccia, A. J., & Le, Q. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2602 · Cited by 11
“HIF-1a–mediated gene transcription represents a major hypoxia regulated signaling pathway and is a valid therapeutic target (16, 44).”
BackgroundMethodSelf-citationAugmenting tumor sensitivity to topotecan by transient hypoxia
Lund, E. L., Hansen, L. T., & Kristjansen, P. E. G. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1008-1 · Cited by 10
“HIF-1a is upregulated in many human tumors and inhibitors of HIF-1a are underway and are currently being tested for their efficacy as anticancer therapeutics [13, 14].”
BackgroundSimanjuntak, M. V., Jauhar, M. M., Syaifie, P. H., Arda, A. G., Mardliyati, E., Shalannanda, W., Hermanto, B. R., & Anshori, I. (2024) · Bioinformatics and Biology Insights · doi:10.1177/11779322231224187 · Cited by 9
“According to Amitai et al, 71 Ma et al, 72 and Giaccia et al, 73 the important residues have a crucial role in drug development, targeting, or drug interaction studies and are generally well conserved in the structure.”
BackgroundHNF-1a promotes pancreatic cancer growth and apoptosis resistance via its target gene PKLR
Fan, Z., Fan, K., Deng, S., Gong, Y., Qian, Y., Huang, Q., Yang, C., He, C., Jin, K., Luo, G., et al. (2020) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmz169 · Cited by 9
Akhlaq, R., Khan, T., Ahmed, T., Musharraf, S. G., & Ali, A. (2023) · Drug Development Research · doi:10.1002/ddr.22045 · Cited by 9
“Whereas PX‐12 interferes with HIF‐1α transactivation by inhibiting Trx‐1 inside the nucleus, Trx‐1 is responsible for the reduction of Redox factor‐1 (Ref‐; Muz et al., 2015).”
BackgroundInfluentialPharmacophore-based 3D-QSAR of HIF-1 inhibitors
Chung, J., Pasha, F. A., Cho, S. J., Won, M., Lee, J. J., & Lee, K. (2009) · Archives of Pharmacal Research · doi:10.1007/s12272-009-1301-3 · Cited by 9
Li, H., Miao, J. H., Zhu, M., Gao, M., Dai, Y., Huo, Q., Ma, T., & Wu, C. (2019) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-019-09799-3 · Cited by 9
Targeting conserved domains of hypoxia-inducible factors for cancer therapy
Salman, S., Huang, T. Y., Hwang, Y., Kumar, A., Datan, E., Wicks, E. E., Cho, E., Lee, S. N., Chen, C. O., Peng, Y., et al. (2026) · The Journal of Experimental Medicine · doi:10.1084/jem.20251009 · Cited by 11
“Hypoxia, defined as decreased O 2 availability, is a common feature of many pathological conditions, including cancer, ischemic cardiovascular disease, and inflammatory disorders (Eltzschig and Carmeliet, 2011; Giaccia et al., 2003; Semenza, 2012a; Yuan et al., 2024).”
Lan, Y., Song, Y., Zhang, W., Zhao, S., Wang, X., Wang, L., Wang, Y., Yang, X., Wu, H., & Liu, X. (2025) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.4c07530 · Cited by 8
Liu, D., Hu, L., Zhang, Z., Li, Q. Y., & Wang, G. (2012) · Molecular Medicine Reports · doi:10.3892/mmr.2012.1237 · Cited by 8
Giannopoulou, A. F., Velentzas, A. D., Anagnostopoulos, A. K., Agalou, A., Papandreou, N. C., Katarachia, S. A., Koumoundourou, D. G., Konstantakou, E. G., Pantazopoulou, V. I., Delis, A. D., et al. (2021) · Cancers · doi:10.3390/cancers13092024 · Cited by 8
Role of cholesterol homeostasis in MASH-driven hepatocellular carcinoma: not just a neutral fat
Ribas, V. (2024) · Exploration of Digestive Diseases · doi:10.37349/edd.2024.00048 · Cited by 9
Advances in herpes simplex virus antiviral therapies
Mamidyala, S. K., & Firestine, S. M. (2006) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.16.11.1463 · Cited by 8
“8 Pyrazolo [1,5-a]pyridines Researchers at GlaxoSmithKline, using a high-throughput antiviral screen, identified the compound GW3733 (65) as a potent antiherpetic agent [84].”
BackgroundKang, P., & Cheng, F. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1660433 · Cited by 7
“Notably, HIF-1 β , as a structural subunit, is constitutively expressed and not regulated by oxygen concentration (Giaccia et al., 2003).”
Cong, J., Zheng, S., Zhang, H., Li, Y., & Liu, Z. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218548 · Cited by 8
FOLR1-Targeted Oxygen-Delivering Nanosomes Enhance Chemo-Induced Apoptosis in Hypoxic Cancer
Lee, G., Kim, J., Yang, J., Jang, Y., Jang, J., Tanaka, M., Niepa, T. H. R., Lee, H.-Y., & Choi, J. H. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s513688 · Cited by 7
Enzyme-Linked Immunosorbent Assay for Pharmacological Studies Targeting Hypoxia-Inducible Factor 1α
Formento, J., Berra, E., Ferruà, B., Magné, N., Simos, G., Brahimi‐Horn, C., Pouysségur, J., & Milano, G. A. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.5.660-664.2005 · Cited by 9
“Fundamental and pharmaceutical research into angiogenesis has lead to the development of new molecules that inhibit HIF-1 (7, 15).”
BackgroundShunaev, V. V., Bobenko, N. G., Korusenko, P. M., Egorushkin, V. E., & Glukhova, O. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021296 · Cited by 7
“Of importance is their role in the behavior of hypoxia-inducible factor 1 alpha (HIF-1α), which is a trigger of fight against different diseases [12,13].”
BackgroundMolecular Determinants of Intrinsic Multidrug Resistance in Cancer Cells and Tumors
Monti, E. (2007) · Humana Press eBooks · doi:10.1007/978-1-59745-035-5_14 · Cited by 7
“, by targeting the HIF-1 transcription factor (5,13), is under way.”
BackgroundHypoxia-driven ncRNAs in breast cancer
Al-Zuaini, H. H., Zahid, K. R., Xiao, X., Raza, U., Huang, Q., & Zeng, T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1207253 · Cited by 13
Retinal and Choroidal Vasculature
Grant, M. B., & Lutty, G. A. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0737-9.00018-7 · Cited by 7
Insight into Evolution and Conservation Patterns of B1-Subfamily Members of GPCR
Chakraborty, C., Sharma, A. R., Sharma, G., Bhattacharya, M., & Lee, S. (2020) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-020-10043-5 · Cited by 7
Wu, X., Deng, Y., Zu, Y., & Yin, J. (2020) · PubMed · Cited by 9
The peptidyl prolyl isomerase, PIN1 induces angiogenesis through direct interaction with HIF-2α
Choi, M., Saeidi, S., Han, H., Kim, S., Kwon, N., Kim, D., Min, S., Choi, B. Y., & Surh, Y. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.08.015 · Cited by 10
Lubell, W. D. (2016) · Topics in heterocyclic chemistry · doi:10.1007/978-3-319-49124-0 · Cited by 7
Fernández-Checa, J. C., & García‐Ruiz, C. (2009) · Springer eBooks · doi:10.1007/978-3-642-00150-5_29 · Cited by 6
Nagao, S., Yamane, Y., Funasaka, S., Tanaka, K., Miyazaki, K., Kotake, Y., Kamata, J., Miyano, S. W., Toyama, O., Ozawa, Y., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.07.020 · Cited by 6
Wang, L., Zhang, M., Gao, X., Li, J., Wu, M., Zhang, X., & Ye, Z. (2022) · RSC Advances · doi:10.1039/d2ra04690c · Cited by 6
Yang, Y., Liu, S., Fan, Z., Li, Z., Liu, J., & Xing, F. (2014) · Microvascular Research · doi:10.1016/j.mvr.2014.03.004 · Cited by 6
Serwe, A., Anke, T., & Erkel, G. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9201-9 · Cited by 6
“In addition, exposure to a variety of growth factors (insulin, insulin-like growth factor-1 (IGF-1), IGF-2, and angiotensin II) has also been shown to increase HIF-1 activity in normoxic and hypoxic conditions and HIF-1α over-expression has been found in many human cancers [ 24 ].”
BackgroundSuares, A., Tapia, C., & Pardo, V. G. (2018) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2018.10.004 · Cited by 6
Yu, R., Chen, R., Shi, Q., Li, T., & Tang, H. (2008) · Surgical Neurology · doi:10.1016/j.surneu.2008.02.038 · Cited by 7
“Given the central role that HIF-1α plays in compensation of loss of oxygen and promotion of concomitant angiogenesis and glycolysis, it is reasonable to speculate that downregulation of HIF-1α activity could be a potent mechanism in prevention of survival or angiogenic activity of various solid tumors [10].”
BackgroundThe Cellular Microenvironment and Metastases
Rankin, E. B., Erler, J. T., & Giaccia, A. J. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00003-5 · Cited by 9
Self-citation
Metadata
- Authors
- Giaccia, A., Siim, B. G., & Johnson, R. S.
- Affiliations
- Stanford Medicine (US)
- University of Auckland (NZ)
- University of California San Diego (US)
- Corresponding author
- Johnson, Randall S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 803-811
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2075880922
- Cited by
- 631
- References
- 116
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 30 · 2019: 14 · 2018: 26 · 2017: 16 · 2016: 20 · 2015: 20 · 2014: 27 · 2013: 30 · 2012: 29
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, hypoxia-inducible factor, hypoxia, therapeutic target, oxygen sensing, transcriptional regulation, cancer, heart disease, stroke, therapeutic targeting
- MeSH terms
- Animals, Cardiovascular Diseases, DNA-Binding Proteins, Gene Expression Regulation, Humans, Neoplasms, Nuclear Proteins, Oxygen, Transcription Factors, Drug Design, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.